Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Lestaurtinib

Generic Name: Lestaurtinib

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₁N_₃O_₄

CAS Number: 111358-88-4

Unique Ingredient Identifier: DO989GC5D1

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in pancreatic cancer, prostate cancer, and leukemia (myeloid).

Associated Conditions

No associated conditions information available.

Clinical Trials

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Phase 2

Completed

Posted: 2008/01/04

Sponsor:

Cephalon

ID:NCT00586651

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 3

Completed

Posted: 2007/11/12

Sponsor:Children's Oncology ...

ID:NCT00557193

CEP-701 for PH-negative Myelofibrosis

Phase 2

Completed

Posted: 2007/06/29

Sponsor:M.D. Anderson Cancer...

ID:NCT00494585

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Posted: 2007/05/07

Sponsor:Children's Oncology ...

ID:NCT00469859

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

Phase 1

Completed

Posted: 2004/06/11

Sponsor:

New Approaches to Ne...

ID:NCT00084422

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy